|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...910111213141516171819...6768» |
- fentanyl citrate / Generic mfg.
New trial: Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies (clinicaltrials.gov) - Aug 31, 2016
P=N/A, N=1101, Completed, Sponsor: Etablissement Fran
- Clinical data, Trial primary completion date: CoMMpass: Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (clinicaltrials.gov) - Aug 26, 2016
P=N/A, N=1154, Active, not recruiting, Sponsor: Multiple Myeloma Research Foundation
Trial primary completion date: Jul 2019 --> Sep 2023
- Biomarker, Enrollment open, Trial initiation date, Trial primary completion date: The Role of Microparticles as a Biomarker (clinicaltrials.gov) - Aug 26, 2016
P=N/A, N=200, Enrolling by invitation, Sponsor: University of Rochester
Trial primary completion date: Jul 2019 --> Sep 2023 Not yet recruiting --> Enrolling by invitation | Initiation date: Jan 2016 --> Jul 2016 | Trial primary completion date: Jan 2018 --> Dec 2019
- || Darzalex IV (daratumumab) / J&J
Clinical: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma (clinicaltrials.gov) - Aug 26, 2016
P2, N=104, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Enrolling by invitation | Initiation date: Jan 2016 --> Jul 2016 | Trial primary completion date: Jan 2018 --> Dec 2019 Trial primary completion date: Dec 2016 --> Jan 2015
- || Darzalex (daratumumab) / J&J
Immunomodulating: Sirius: An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD (clinicaltrials.gov) - Aug 26, 2016
P2, N=124, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Dec 2016 --> Jan 2015 Trial primary completion date: Oct 2016 --> Jan 2015
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (clinicaltrials.gov) - Aug 24, 2016
P2, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2016 --> Jan 2015 Trial primary completion date: Jul 2017 --> Jul 2018
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg., bendamustine / Generic mfg.
Trial completion: Bendamustine, Lenalidomide (Revlimid (clinicaltrials.gov) - Aug 24, 2016
P2, N=50, Completed, Sponsor: Cantonal Hospital of St. Gallen
Trial primary completion date: Jul 2017 --> Jul 2018 Active, not recruiting --> Completed
- ||| Mozobil (plerixafor) / Sanofi
Trial completion, Phase classification, Trial initiation date, Trial primary completion date: Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor (clinicaltrials.gov) - Aug 24, 2016
P=N/A, N=7801, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | Initiation date: Jan 2008 --> Mar 2011 | Trial primary completion date: Dec 2016 --> Jun 2016
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Trial primary completion date: Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma (clinicaltrials.gov) - Aug 24, 2016
P1/2, N=55, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | Initiation date: Jan 2008 --> Mar 2011 | Trial primary completion date: Dec 2016 --> Jun 2016 Trial primary completion date: May 2016 --> May 2017
- rVIIa-FP (CSL689) / CSL Behring
Enrollment closed: Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency (clinicaltrials.gov) - Aug 24, 2016
P1, N=16, Active, not recruiting, Sponsor: CSL Behring
Trial primary completion date: May 2016 --> May 2017 Recruiting --> Active, not recruiting
- ||| bortezomib / Generic mfg., pegylated liposomal doxorubicin / Generic mfg., bendamustine / Generic mfg.
Enrollment closed, Combination therapy: Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma (clinicaltrials.gov) - Aug 23, 2016
P1/2, N=69, Active, not recruiting, Sponsor: Sherif Farag, MB, BS
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Ixinity (trenonacog alfa) / Medexus, Emergent Biosolutions
Enrollment change, Trial withdrawal: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B (clinicaltrials.gov) - Aug 23, 2016
P3, N=0, Withdrawn, Sponsor: Cangene Corporation
Recruiting --> Active, not recruiting N=18 --> 0 | Not yet recruiting --> Withdrawn
- || Zontivity (vorapaxar) / Merck (MSD)
Trial primary completion date: ADVICE: Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints (clinicaltrials.gov) - Aug 23, 2016
P1/2, N=60, Recruiting, Sponsor: Kirby Institute
N=18 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Aug 2016 --> Sep 2017
- Darzalex (daratumumab) / J&J
Enrollment closed, Phase classification, Combination therapy: A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 23, 2016
P1b, N=8, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Trial primary completion date: Aug 2016 --> Sep 2017 Recruiting --> Active, not recruiting | Phase classification: P1 --> P1b
- Biomarker, Trial completion: Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy (clinicaltrials.gov) - Aug 22, 2016
P1, N=18, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting | Phase classification: P1 --> P1b Active, not recruiting --> Completed
- | Caprelsa (vandetanib) / Sanofi
Trial completion: Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer (clinicaltrials.gov) - Aug 22, 2016
P2, N=30, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||| Enrollment open: A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (? 65 Years) With Haematologic Neoplasms (clinicaltrials.gov) - Aug 20, 2016
P=N/A, N=80, Recruiting, Sponsor: Celgene Corporation
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion, Enrollment change, Metastases: Umbilical Cord Blood Transplant for Hematological Malignancies (clinicaltrials.gov) - Aug 19, 2016
P1, N=5, Completed, Sponsor: University of Pennsylvania
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=36 --> 5
- New trial: Institut Paoli Calmettes Multiple Myeloma Database (clinicaltrials.gov) - Aug 17, 2016
P=N/A, N=5000, Recruiting, Sponsor: Institut Paoli-Calmettes
- New trial: Coaguchek: Utility of Point-of-care Device for Rapid Determination of Cogulopathy in Trauma Patients (clinicaltrials.gov) - Aug 17, 2016
P=N/A, N=100, Completed, Sponsor: University Hospital, Grenoble
- New trial: National Survey of People With Haemophilia in Portugal (clinicaltrials.gov) - Aug 17, 2016
P=N/A, N=477, Not yet recruiting, Sponsor: University of Minho
- New trial, HEOR: PSY_HaEMOPEQ: Effectiveness of Psychological Interventions in Haemophilia (clinicaltrials.gov) - Aug 17, 2016
P=N/A, N=66, Not yet recruiting, Sponsor: University of Minho
- || Nplate (romiplostim) / Amgen, Kyowa Kirin
New P3 trial: Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Aug 15, 2016
P3, N=200, Recruiting, Sponsor: Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.
- Nplate (romiplostim) / Amgen, Kyowa Kirin
New P1/2 trial: Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Aug 15, 2016
P1/2, N=24, Recruiting, Sponsor: Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.
- || Trial primary completion date: Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation (clinicaltrials.gov) - Aug 15, 2016
P=N/A, N=300, Recruiting, Sponsor: Octapharma
Active, not recruiting --> Completed | N=36 --> 5 Trial primary completion date: Feb 2017 --> Dec 2019
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma, Rituxan (rituximab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Aug 15, 2016
P1, N=1, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Feb 2017 --> Dec 2019 Recruiting --> Active, not recruiting | N=14 --> 1 | Trial primary completion date: Dec 2016 --> Aug 2016
- befovacimab (BAY 1093884) / Bayer
Enrollment change: A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors (clinicaltrials.gov) - Aug 15, 2016
P1, N=34, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=14 --> 1 | Trial primary completion date: Dec 2016 --> Aug 2016 N=26 --> 34
- bortezomib / Generic mfg.
Enrollment change, Trial primary completion date, Residual disease, Minimal residual disease: First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade (clinicaltrials.gov) - Aug 12, 2016
P2, N=37, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
N=26 --> 34 N=100 --> 37 | Trial primary completion date: Dec 2015 --> Oct 2016
- New P4 trial: Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility Trial (clinicaltrials.gov) - Aug 12, 2016
P4, N=32, Recruiting, Sponsor: University of Sao Paulo General Hospital
- Istodax (romidepsin) / Astellas, BMS, Rituxan (rituximab) / Roche
Enrollment change, Trial initiation date, Trial withdrawal: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Aug 11, 2016
P1/2, N=0, Withdrawn, Sponsor: Mayo Clinic
N=100 --> 37 | Trial primary completion date: Dec 2015 --> Oct 2016 N=56 --> 0 | Initiation date: Jun 2016 --> Oct 2016 | Not yet recruiting --> Withdrawn
- bortezomib / Generic mfg., lenalidomide / Generic mfg., sirolimus / Generic mfg.
Trial completion, Phase classification, Trial primary completion date: EMN-alloRIC: Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation (clinicaltrials.gov) - Aug 11, 2016
P2, N=45, Completed, Sponsor: European Myeloma Network
N=56 --> 0 | Initiation date: Jun 2016 --> Oct 2016 | Not yet recruiting --> Withdrawn Recruiting --> Completed | Phase classification: P1/2 --> P2 | Trial primary completion date: Dec 2015 --> May 2016
- ||| Xyntha (moroctocog alfa) / Pfizer
Enrollment closed: PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A (clinicaltrials.gov) - Aug 11, 2016
P4, N=90, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Completed | Phase classification: P1/2 --> P2 | Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Active, not recruiting
- everolimus / Generic mfg., bendamustine / Generic mfg.
Trial primary completion date: Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Aug 10, 2016
P1, N=18, Recruiting, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting Trial primary completion date: May 2016 --> Dec 2016
- Mozobil (plerixafor) / Sanofi
New trial, HEOR: Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma (clinicaltrials.gov) - Aug 10, 2016
P=N/A, N=60, Completed, Sponsor: Institut Paoli-Calmettes
- pegylated liposomal doxorubicin / Generic mfg., carfilzomib / Generic mfg.
Clinical: Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 10, 2016
P1/2, N=53, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Jul 2016 --> Feb 2017
- |||| Tavalisse (fostamatinib) / Rigel
Trial primary completion date: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Aug 8, 2016
P3, N=75, Active, not recruiting, Sponsor: Rigel Pharmaceuticals
Trial primary completion date: Jul 2016 --> Feb 2017 Trial primary completion date: Jun 2016 --> Sep 2016
- lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients (clinicaltrials.gov) - Aug 8, 2016
P2, N=32, Recruiting, Sponsor: University Health Network, Toronto
Trial primary completion date: Jun 2016 --> Sep 2016 Trial primary completion date: Aug 2016 --> Dec 2016
- carfilzomib / Generic mfg.
Clinical: Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy (clinicaltrials.gov) - Aug 8, 2016
P2, N=10, Terminated, Sponsor: Attaya Suvannasankha
Trial primary completion date: Aug 2016 --> Dec 2016 Active, not recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Jan 2016; Slow accrual
- Enrollment open, Trial initiation date: iTACTIC: Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy (clinicaltrials.gov) - Aug 8, 2016
P2, N=392, Recruiting, Sponsor: Queen Mary University of London
Active, not recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Jan 2016; Slow accrual Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Jun 2016
- New P2 trial: Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 (clinicaltrials.gov) - Aug 8, 2016
P2, N=40, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire, Amiens
- lenalidomide / Generic mfg., thalidomide / Generic mfg.
Enrollment closed: Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) (clinicaltrials.gov) - Aug 4, 2016
P=N/A, N=17, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change, HEOR: PWBCD: Socialization of Adult Men With Congenital Hemophilia A or B (clinicaltrials.gov) - Aug 4, 2016
P=N/A, N=27, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Completed | N=60 --> 27
- ||||||| Tavalisse (fostamatinib) / Rigel
Trial completion: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Aug 2, 2016
P3, N=75, Completed, Sponsor: Rigel Pharmaceuticals
Recruiting --> Completed | N=60 --> 27 Active, not recruiting --> Completed
- ||||||| NovoEight (turoctocog alfa) / Novo Nordisk
Trial completion: Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 (clinicaltrials.gov) - Aug 2, 2016
P3, N=214, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P1 trial: END-HEMO: Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study. (clinicaltrials.gov) - Aug 1, 2016
P1, N=18, Recruiting, Sponsor: University Hospital, Toulouse
- ||| bortezomib / Generic mfg., dexamethasone / Generic mfg., bendamustine / Generic mfg.
Enrollment change: Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy (clinicaltrials.gov) - Jul 29, 2016
P2, N=59, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed N=42 --> 59
- Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: PROPRIO-HE: Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=17, Completed, Sponsor: Universidad Católica San Antonio de Murcia
N=42 --> 59 Not yet recruiting --> Completed | N=30 --> 17 | Initiation date: May 2015 --> Sep 2015 | Trial primary completion date: May 2015 --> Oct 2015
- ||| CB-5083 / Cleave Therap
Enrollment open, Enrollment change, Trial primary completion date: A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (clinicaltrials.gov) - Jul 28, 2016
P1, N=120, Recruiting, Sponsor: Cleave Biosciences, Inc.
Not yet recruiting --> Completed | N=30 --> 17 | Initiation date: May 2015 --> Sep 2015 | Trial primary completion date: May 2015 --> Oct 2015 Active, not recruiting --> Recruiting | N=50 --> 120 | Trial primary completion date: Dec 2016 --> Dec 2018
- Trial primary completion date: Familial Myeloproliferative Disorders (clinicaltrials.gov) - Jul 28, 2016
P=N/A, N=200, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Recruiting | N=50 --> 120 | Trial primary completion date: Dec 2016 --> Dec 2018 Trial primary completion date: Jun 2016 --> Jun 2017
- GO-203-2c / Genus Oncology
Trial initiation date, Combination therapy: GO-203-2C + Bortezomib For Relapsed Or Refractory MM (clinicaltrials.gov) - Jul 28, 2016
P1, N=28, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jun 2016 --> Jun 2017 Initiation date: Feb 2016 --> Dec 2016